Oruka Therapeutics' Arjun Agarwal sells 10,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. (ORKA) reported that Senior Vice President, Finance Arjun Agarwal exercised options covering 8,542 and 1,458 common shares at exercise prices of $12.50 and $34.39 per share, respectively, on November 12, 2026. He also sold 10,000 common shares that day in six transactions; the reported weighted-average prices for those sale tranches ranged from $101.9758 to $107.0000 per share. The sales were made under a Rule 10b5-1 trading plan entered into February 11, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) F7 | 8,542 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) F8 | 1,458 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,542 | $12.50 | $107K |
| Exercise | Common Stock | 1,458 | $34.39 | $50K |
| Sale | Common Stock F1, F2 | 500 | $101.9758 | $51K |
| Sale | Common Stock F1, F3 | 801 | $103.1556 | $83K |
| Sale | Common Stock F1, F4 | 799 | $104.2502 | $83K |
| Sale | Common Stock F1, F5 | 6,842 | $105.2806 | $720K |
| Sale | Common Stock F1, F6 | 958 | $106.1759 | $102K |
| Sale | Common Stock F1 | 100 | $107.00 | $11K |
Footnotes (8)
- F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.22, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.75 to $103.70, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $104.65, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.82 to $105.81, inclusive.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.82 to $106.52, inclusive.
- F7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
- F8. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
Employee Stock Option (right to buy) financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were the vesting terms for Arjun Agarwal's exercised ORKA options?
AI-generated analysis. How Rhea-AI works. Not financial advice.